BAJAJ BROKING

Notification
No new Notification messages
Chamunda Electrical Ltd IPO is Open!
Apply for the Chamunda Electrical Ltd IPO through UPI in just minutes.
Q3 FY'25 Results of Top Companies!
From Reliance Industries to TCS to HDFC Bank, check out the latest quarterly results with financial highlights, key performance metrics, and more!
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Sun Pharmaceutical Industries Q3 Results FY24-25: Revenue Increases by 1294.76 Crore YoY, Net Profit Increases by 352.44 Crore YoY

Sun Pharmaceutical Q3 Results FY24-25

Sun Pharmaceutical Industries has announced its financial results for the third quarter of the fiscal year 2024-2025, showcasing significant growth in both revenue and net profit. The company's consolidated revenue from operations reached ₹13675.46 crore, marking a notable increase from ₹12380.70 crore in the same quarter of the previous year. Net profit after tax also saw a substantial rise, amounting to ₹2912.98 crore compared to ₹2560.54 crore in the corresponding quarter last year.

SUN PHARMACEUTICAL IND L

Trade

1742.2-1.75 (-0.10 %)

Updated - 01 February 2025
1789.00day high
DAY HIGH
1733.30day low
DAY LOW
1437588
VOLUME (BSE)

Key Highlights/Quick Insights of Sun Pharmaceutical Industries Q3 Results

  • Revenue Growth: The company achieved a 10.5% year-over-year increase in revenue from operations, rising from ₹12380.70 crore in Q3 FY23-24 to ₹13675.46 crore in Q3 FY24-25.

  • Net Profit Increase: Net profit after tax grew by 13.8%, reaching ₹2912.98 crore in the current quarter, up from ₹2560.54 crore in the same period last year.

  • Total Income: Total income for the quarter stood at ₹14141.08 crore, compared to ₹12630.90 crore in Q3 FY23-24.

  • Total Expenses: The company's total expenses were ₹10348.51 crore, up from ₹9560.74 crore in the previous year's corresponding quarter.

Quarterly Sun Pharmaceutical Industries Q3 Results FY24-25  

In the third quarter of FY24-25, Sun Pharmaceutical Industries reported a consolidated revenue from operations of ₹13675.46 crore, reflecting a 10.5% increase from ₹12380.70 crore in Q3 FY23-24. Other income also saw a significant rise, totaling ₹4,65.62 crore, up from ₹250.20 crore in the same quarter last year. Consequently, the total income reached ₹14141.08 crore, compared to ₹12630.90 crore in the previous year's corresponding quarter.

The company's total expenses increased to ₹10348.51 crore from ₹9560.74 crore in Q3 FY23-24. Despite the rise in expenses, profit before tax (PBT) grew to ₹3476.40 crore, up from ₹3000.35 crore in the same period last year. After accounting for a tax expense of ₹558.86 crore, net profit after tax (PAT) stood at ₹2912.98 crore, a 13.8% increase from ₹2560.54 crore in Q3 FY23-24.

Segment Highlights

India Formulations:

  • Sales: ₹4,300.4 crore, up 13.8% year-over-year.

  • Contribution: Approximately 32% of total consolidated sales.

  • Nine-month Sales: ₹12,710.0 crore, a 13.7% increase over the same period last year.

  • Market Share: Increased from 7.8% to 8.2% in the ₹2,21,400 crore Indian pharmaceutical market (AIOCD AWACS MAT Dec-2024).

  • Prescription Rankings: Ranked No.1 by prescriptions in 12 doctor categories (SMSRC, July-Oct 2024).

  • New Products: Launched 12 new products in Q3FY25.

US Formulations:

  • Sales: US$474 million, a slight decline of 0.7% from the previous year.

  • Contribution: Approximately 30% of total consolidated sales.

  • Nine-month Sales: US$1,457 million, a 5.7% growth over the same period last year.

Emerging Markets (EM) Formulations:

  • Sales: US$277 million, a 10.1% increase year-over-year.

  • Contribution: Approximately 17% of total consolidated sales.

  • Nine-month Sales: US$854 million, up 7.2% over the same period last year.

Rest of World (ROW) Formulations:

  • Sales: US$259 million, a significant growth of 21.0% compared to the previous year.

  • Contribution: Approximately 16% of total consolidated sales.

  • Nine-month Sales: US$647 million, a 5.2% increase over the same period last year.

Active Pharmaceutical Ingredients (API):

  • External Sales: ₹567.8 crore, a 21.8% rise year-over-year.

  • Nine-month Sales: ₹1,596.2 crore, growing by 6.2% over the same period last year.

Research & Development (R&D):

  • Investment: ₹845.0 crore in Q3FY25, accounting for 6.3% of sales, compared to ₹824.5 crore in Q3FY24.

  • Nine-month R&D Expense: ₹2,431.9 crore, representing 6.2% of sales.

Also read: Dr Reddy's Q3 Results FY24-25 Highlights, Revenue Up 16% YoY, Net Profit at ₹1,413.3 Crore (Consolidated)

Sector expectations for Sun Pharmaceutical Industries Q3 Results FY24-25
The pharmaceutical sector anticipated robust performance from Sun Pharmaceutical Industries in Q3 FY24-25, given the company's strategic initiatives and expanding specialty product portfolio. The reported results, with significant increases in both revenue and net profit, align with these expectations and underscore the company's strong position in the industry.

Management Commentary

Dilip Shanghvi, Chairman and Managing Director of the Company said, “Our performance in the quarter showed all-round improvement. Product sales in Global Specialty crossed 1/5th of overall sales. Our market share gain in India has been driven by industry leading volume growth. Emerging Markets demonstrated strong performance in spite of currency challenges across geographies. All our businesses remain well positioned for future.”

This information is sourced from BSE.

Financial Table – With All Major Metrices and Numbers (Consolidated)

Particulars

31-12-2024 (₹ million)

31-12-2023 (₹ million)

Revenue from Operations

136,754.6

123,807.0

Other Income

4,656.2

2,502.0

Total Income

141,410.8

126,309.0

Total Expenses

103,485.1

95,607.4

Profit Before Tax (PBT)

34,764.0

30,003.5

Tax Expense (Net)

5,588.6

4,323.2

Net Profit After Tax (PAT)

29,129.8

25,605.4

Note: All financial figures are sourced from Sun Pharmaceutical Industries’s official quarterly earnings report.

The financial data for Sun Pharmaceutical Industries Q3 FY24-25 results is sourced from BSE.

Sun Pharmaceutical Industries Q3 Results FY24-25: Projected 10% YoY Revenue Increase

Sun Pharmaceutical Industries is scheduled to announce its Q3 FY24-25 earnings on January 31, 2025. Analysts anticipate steady double-digit growth in both the Indian and U.S. markets, contributing to a mid-teen increase in net profit. According to a Moneycontrol poll of 10 brokerages, the company's net profit is projected to rise by 15% to ₹2,893 crore, up from ₹2,524 crore in the same quarter of the previous fiscal year. Revenue is expected to increase by 10% to ₹13,375 crore, compared to ₹12,157 crore in the prior year. However, operational performance may experience a slight decline due to a reduced contribution from the cancer drug Revlimid. EBITDA margins are forecasted to decrease by 20 basis points year-over-year to 27.9% in Q3.

Key Highlights:

  • Revenue Growth: Estimated 10% year-over-year increase to ₹13,375 crore.

  • Net Profit: Projected 15% rise to ₹2,893 crore.

  • EBITDA Margin: Expected to decline by 20 basis points to 27.9%.

  • India Business: Continued double-digit growth anticipated.

  • U.S. Business: Sustained double-digit growth expected.

  • Revlimid Contribution: Anticipated decrease impacting operational performance.

Quarterly Performance Overview:

In the upcoming Q3 FY24-25 results, Sun Pharma is expected to report a 10% increase in revenue, reaching ₹13,375 crore, driven by robust performance in both domestic and international markets. The net profit is projected to grow by 15% to ₹2,893 crore, reflecting strong operational efficiency. Despite these positive trends, the EBITDA margin is anticipated to experience a slight decline of 20 basis points, settling at 27.9%, primarily due to a lower contribution from Revlimid.

Note: These figures are based on analyst estimates and are subject to change upon the official release of Sun Pharmaceutical Industries's financial results.

The financial data estimates for Sun Pharmaceutical Industries Q3 FY24-25 results are sourced from Money Control.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text